Re: OTC Expert & Grey Market Restrictions
in response to
by
posted on
Nov 22, 2022 11:22AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
As I recall, DM wasn't happy that ZHCLF started trading on the OTC. Can't blame them. It had to be making private placements more difficult. It's been great for folks who wanted to pick up some cheap shares. And now it looks like we wait for a deal or buyout and hope they put some $$$ in our pockets.